This paper reviews evidence from April, 1998 through April 2002 for the dopaminergic
treatment of the restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) …

Recent evidence suggests that the placebo effect is mediated by the dopaminergic reward
mechanisms in the human brain and that it is related to the expectation of clinical benefit. On …

Background: There is a need for an easily administered instrument which can be applied to
all patients with restless legs syndrome (RLS) to measure disease severity for clinical …

The past decade has seen an explosion of interest in both idiopathic and secondary restless
legs syndrome (RLS). Secondary RLS occurs in patients with uremia, pregnancy, and iron …

Dopamine agonists for the treatment of restless legs syndrome - Scholz, H - 2011 | Cochrane
Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …

In 2003, the EFNS Task Force was set up for putting forth guidelines for the management of
the Restless Legs Syndrome (RLS) and the Periodic Limb Movement Disorder (PLMD). After …

Patients with restless legs syndrome (RLS) suffer from sensory and motor symptoms evoked
in the limbs at rest. Symptoms increase in the evening and during the night. The circadian …

Background Controlled clinical trials robustly demonstrate the short-term efficacy of
dopamine agonists (DA) for restless legs syndrome (RLS), but little is known about the long …

Restless legs syndrome (RLS) is a common neurologic disorder that affects 5 to 10% of the
population and increases in prevalence with aging. The clinical hallmarks of RLS include …

Background: Restless legs syndrome (RLS) and periodic limb movements during sleep
(PLMS) have been known for over 300 years, and they may be present in as many as 25 …